Omadacycline: A Novel Tetracycline-Class Antibiotic and Research Progress on Its Impurities
Omadacycline is a novel third-generation tetracycline-class antibiotic developed by Paratek Pharmaceuticals of the United States. The drug was approved by the FDA and marketed in 2018 under the trade name Nuzyra®. Omadacycline is mainly used to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Compared with other tetracycline drugs, omadacycline has been optimized in chemical structure by introducing new substituent groups at the C7 and C9 positions, thereby improving its affinity and stability for bacterial ribosomes and overcoming common tetracycline resistance mechanisms such as efflux pumps and ribosomal protection proteins.
Omadacycline exhibits strong bacteriostatic effects against a broad range of bacteria, including Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, atypical bacteria, and other drug-resistant bacteria.
In April 2017, Zai Lab reached a collaboration with Paratek and obtained the exclusive rights to develop and commercialize omadacycline in the Chinese market. In February 2020, the National Medical Products Administration (NMPA) accepted the new drug marketing application for omadacycline, and in May of the same year granted it priority review status.
At present, there are relatively few literature reports on the impurities of omadacycline, mainly focusing on the manufacturing process and quality research.
The synthesis process of omadacycline uses doxycycline as the starting material and involves multiple steps, such as selective protection, C9 aminomethylation, C7 pyrrolidination, deprotection, and reductive amination. During this process, various process impurities and degradation impurities may be produced, including C9-position isomers, deaminated derivatives, exocyclic double-bond isomers, and formylated impurities.
Impurity detection of omadacycline mainly uses high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). In terms of quality control, both the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP) have included quality standards and testing methods for omadacycline, including limit requirements for related substances, residual solvents, and other impurities. Among them, the limit for a single impurity is usually 0.1% to 0.2%, and total impurities are controlled within 1.0%. Some process impurities may have potential cytotoxicity or mutagenicity and require strict control of their limits, such as formylated impurities.
As a novel tetracycline-class antibiotic, impurity research on omadacycline still needs to be deepened. Systematically carrying out impurity profiling, degradation mechanism, and stability studies of omadacycline, and establishing a reasonable quality control strategy, are of great significance for ensuring its safety and efficacy and avoiding adverse reactions.
CATO Products
In response to customer demand for omadacycline-related impurity products, CATO provides supporting impurity reference standards for omadacycline, with in-stock inventory, and welcomes your inquiries at any time. CATO's sales and technical teams will provide comprehensive product information and professional technical consulting services according to your specific needs.
